The malignant melanoma market has become increasingly crowded in recent years with novel treatments expanding therapy options for patients and segmenting the market according to BRAF mutational…
Osteoarthritic (OA) pain represents the second-largest segment of the overall chronic pain market, affecting more than 70 million patients with OA in the G7. The OA pain market represents a…
Introduction: The moderate to severe rheumatoid arthritis (RA) market is crowded; multiple targeted therapies are available, including nine different branded biologics, a biosimilar, and a small-…
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different systems and organs of the body and manifest with a wide spectrum of clinical symptoms. Lupus nephritis (LN) is…
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant…
Market Outlook The dynamics within the LABA/ICS FDC, LAMA, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s …
Hepatocellular carcinoma is a primary malignancy of the liver; the majority of cases arise from underlying liver cirrhosis. Treatment of hepatocellular carcinoma incorporates a variety of…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma ( NHL ) therapy market over the…
Muscular dystrophies (MDs) are a spectrum of genetic disorders characterized by muscle weakness that in severe disease forms can lead to loss of ambulation and early death. MDs share common…
The Emerging Biosimilars Overview offers extensive coverage of the global biosimilar development landscape. We track over 350 currently available and novel biosimilar products, detailing…
In the atopic dermatitis market, topical therapies have been the mainstay of treatment, especially for patients with a mild to moderate form of the disease. Conventional systemic immunosuppressants…
The atopic dermatitis (AD) market is poised to undergo a revolution owing to recent advances in understanding of disease pathology, the recent approval of topical crisaborole (Pfizer’s Eucrisa)…
Treatment of unresectable locally advanced or metastatic bladder cancer has remained relatively unchanged since the early 1990s; chemotherapy regimens are still the mainstay of treatment. However…
The HER2-positive breast cancer treatment paradigm has undergone considerable change in recent years and is expected to evolve further as more novel therapies enter the market. The enthusiastic…
NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…